121 related articles for article (PubMed ID: 23154542)
21. Association of Merkel cell polyomavirus infection with EGFR mutation status in Chinese non-small cell lung cancer patients.
Xu S; Jiang J; Yu X; Sheng D; Zhu T; Jin M
Lung Cancer; 2014 Mar; 83(3):341-6. PubMed ID: 24485957
[TBL] [Abstract][Full Text] [Related]
22. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY
Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
[TBL] [Abstract][Full Text] [Related]
23. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
[TBL] [Abstract][Full Text] [Related]
24. EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery.
Helland Å; Skaug HM; Kleinberg L; Iversen ML; Rud AK; Fleischer T; Sagerup C; Solberg S; Jørgensen L; Ariansen S; Brustugun OT
J Thorac Oncol; 2011 May; 6(5):947-50. PubMed ID: 21623266
[TBL] [Abstract][Full Text] [Related]
25. Can EGFR mutations in plasma or serum be predictive markers of non-small-cell lung cancer? A meta-analysis.
Wu Y; Liu H; Shi X; Song Y
Lung Cancer; 2015 Jun; 88(3):246-53. PubMed ID: 25837799
[TBL] [Abstract][Full Text] [Related]
26. Impact of molecular pathology on the clinical management of lung cancer.
Brambilla E; Brambilla C; Lantuejoul S
Respiration; 2005; 72(3):229-32. PubMed ID: 15942289
[No Abstract] [Full Text] [Related]
27. Prognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligands in non-small cell lung carcinoma patients.
Haghgoo SM; Khosravi A; Mortaz E; Pourabdollah-Toutkaboni M; Seifi S; Sabour S; Allameh A
Clin Biochem; 2017 Apr; 50(6):293-300. PubMed ID: 27923629
[TBL] [Abstract][Full Text] [Related]
28. Circulating plasma microRNAs as potential markers to identify EGFR mutation status and to monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with advanced non-small cell lung cancer.
Qu L; Li L; Zheng X; Fu H; Tang C; Qin H; Li X; Wang H; Li J; Wang W; Yang S; Wang L; Zhao G; Lv P; Lei Y; Zhang M; Gao H; Song S; Liu X
Oncotarget; 2017 Jul; 8(28):45807-45824. PubMed ID: 28496005
[TBL] [Abstract][Full Text] [Related]
29. The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.
Na II; Rho JK; Choi YJ; Kim CH; Park JH; Koh JS; Ryoo BY; Yang SH; Lee JC
Lung Cancer; 2007 Jul; 57(1):96-102. PubMed ID: 17337084
[TBL] [Abstract][Full Text] [Related]
30. The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors.
Chen YM; Lai CH; Chang HC; Chao TY; Tseng CC; Fang WF; Wang CC; Chung YH; Wang YH; Su MC; Huang KT; Chen HC; Lin MC
Lung Cancer; 2016 Mar; 93():47-54. PubMed ID: 26898614
[TBL] [Abstract][Full Text] [Related]
31. First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation.
Kempf E; Lacroix L; Soria JC
Clin Lung Cancer; 2015 Nov; 16(6):e259-61. PubMed ID: 26206728
[No Abstract] [Full Text] [Related]
32. [Driven Gene in Patients with Lung Squamous Cell Carcinoma:
Analysis of Clinicopathologic Characteristics and Prognosis].
Zhang T; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
[TBL] [Abstract][Full Text] [Related]
33. MEK1 and AKT2 mutations in Japanese lung cancer.
Sasaki H; Hikosaka Y; Kawano O; Moriyama S; Yano M; Fujii Y
J Thorac Oncol; 2010 May; 5(5):597-600. PubMed ID: 20354455
[TBL] [Abstract][Full Text] [Related]
34. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor mutations: effect on volume doubling time of non-small-cell lung cancer patients.
Nakamura R; Inage Y; Tobita R; Mori K; Numata T; Yanai H; Endo T; Ohtani H; Satoh H; Yuzawa K; Koizumi M; Ueki H
J Thorac Oncol; 2014 Sep; 9(9):1340-4. PubMed ID: 24481317
[TBL] [Abstract][Full Text] [Related]
36. The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer.
Al-Saad S; Richardsen E; Kilvaer TK; Donnem T; Andersen S; Khanehkenari M; Bremnes RM; Busund LT
PLoS One; 2017; 12(7):e0181527. PubMed ID: 28742836
[TBL] [Abstract][Full Text] [Related]
37. Difference in clonality as a tool for differential diagnosis of primary versus secondary lung neoplasms.
Leuzzi G; Cesario A; Vita ML; Parisi AM; Petrone G; Martini M; Rindi G; Granone P
J Thorac Oncol; 2012 May; 7(5):934-6. PubMed ID: 22722795
[No Abstract] [Full Text] [Related]
38. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.
Tomizawa Y; Iijima H; Sunaga N; Sato K; Takise A; Otani Y; Tanaka S; Suga T; Saito R; Ishizuka T; Dobashi K; Minna JD; Nakajima T; Mori M
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6816-22. PubMed ID: 16203769
[TBL] [Abstract][Full Text] [Related]
39. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer.
Park S; Holmes-Tisch AJ; Cho EY; Shim YM; Kim J; Kim HS; Lee J; Park YH; Ahn JS; Park K; Jänne PA; Ahn MJ
J Thorac Oncol; 2009 Jul; 4(7):809-15. PubMed ID: 19487967
[TBL] [Abstract][Full Text] [Related]
40. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F
Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
